AM 720 KDWN
News, Traffic, Weather

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has voted to endorse an experimental stool test that uses DNA to detect colon cancer and precancerous growths.

The FDA’s panel of genetic experts voted 10-0 that the benefits of Exact Sciences’ Cologuard test outweigh its risks. The vote amounts to a recommendation for the FDA to approve the test from Exact Sciences. The agency is not required to follow the panel’s advice, but often does.

Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and precancerous polyps.

Cologuard and other DNA tests in development detect minute genetic changes associated with cancer cells in the colon.

Colonoscopy is the most accurate test, but many adults are reluctant to undergo the invasive procedure.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.

FDA panel narrowly backs DNA colon cancer test

KDWN

WASHINGTON (AP) — A panel of Food and Drug Administration advisers has narrowly backed an experimental blood test that uses patients’ DNA to help screen for colon cancer.

The FDA’s genetic experts voted 5-4, with one abstention, that the benefits of Epigenomics’ test outweigh the risks. The vote amounts to a recommendation for approval of the company’s Epi proColon kit. The FDA is not required to follow the panel’s recommendation.

Doctors have long used stool tests to look for hidden blood that can be an early warning of cancer. Epigenomics’ test is part of a new wave of diagnostics that detect genetic markers associated with cancerous tumors.

FDA scientists said in their review earlier this week that Epi proColon did not meet all of its accuracy goals in testing against older, stool-based technology.